Crossmark

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

Published Online: 2019-08-20

Published Print: 2019-12

Authors

Tesser, John http://orcid.org/0000-0002-2706-7171
Kafka, Shelly

DeHoratius, Raphael J.

Xu, Stephen

Hsia, Elizabeth C.

Turkiewicz, Anthony
Funding

Funding for this research was provided by:

Janssen Research and Development
License Information

Text and Data Mining valid from 2019-08-20

Version of Record valid from 2019-08-20
More Information

Article History

Received: 22 December 2018

Accepted: 25 July 2019

First Online: 20 August 2019

Ethics approval and consent to participate

: The GO-FURTHER trial was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by the Institutional Review Board or ethics committee at each site. All patients gave written informed consent before any study-related procedures were performed.

: Not applicable.

: JT has received consulting and speaker fees and research support from AbbVie, Amgen, Janssen, Lilly, and Pfizer. AT has received consulting and speaker fees and research support from AbbVie, Janssen, Lilly, Medac, Novartis, Pfizer, and Regeneron. SK, RJD, SX, and ECH are or were employees of Janssen Research & Development, LLC. at the time this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC. is a wholly-owned subsidiary.

Document is current